Aberdeen Group
ONC

Aberdeen Group’s BeOne Medicines Ltd ONC Stock Holding History

Aberdeen Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,913
Closed -$2.75M – 970
2024
Q4 		$2.75M Sell
14,913
-13,006
-47% -$2.66M 0.01% 724
2024
Q3 		$6.27M Sell
27,919
-5,149
-16% -$926K 0.01% 614
2024
Q2 		$4.72M Buy
33,068
+11,930
+56% +$1.84M 0.01% 635
2024
Q1 		$3.31M Hold
21,138
– – 0.01% 727
2023
Q4 		$3.81M Buy
21,138
+19,677
+1,347% +$3.56M 0.01% 714
2023
Q3 		$263K Hold
1,461
– – ﹤0.01% 861
2023
Q2 		$260K Hold
1,461
– – ﹤0.01% 886
2023
Q1 		$315K Hold
1,461
– – ﹤0.01% 870
2022
Q4 		$321K Sell
1,461
-11,394
-89% -$2.09M ﹤0.01% 866
2022
Q3 		$1.73M Buy
12,855
+2,345
+22% +$403K 0.01% 728
2022
Q2 		$1.7M Buy
10,510
+6,018
+134% +$940K 0.01% 732
2022
Q1 		$847K Sell
4,492
-49
-1% -$10.4K ﹤0.01% 843
2021
Q4 		$1.23M Buy
4,541
+306
+7% +$103K ﹤0.01% 848
2021
Q3 		$1.54M Buy
4,235
+230
+6% +$75.2K ﹤0.01% 831
2021
Q2 		$1.37M Buy
4,005
+44
+1% +$14.6K ﹤0.01% 832
2021
Q1 		$1.38M Buy
3,961
+915
+30% +$303K ﹤0.01% 822
2020
Q4 		$787K Sell
3,046
-11,360
-79% -$3.13M ﹤0.01% 852
2020
Q3 		$4.13M Buy
14,406
+1,106
+8% +$260K 0.01% 591
2020
Q2 		$2.5M Buy
13,300
+180
+1% +$29.3K 0.01% 668
2020
Q1 		$1.61M Buy
13,120
+881
+7% +$138K 0.01% 699
2019
Q4 		$2.03M Sell
12,239
-2,282
-16% -$379K ﹤0.01% 722
2019
Q3 		$1.78M Buy
14,521
+3,300
+29% +$438K ﹤0.01% 730
2019
Q2 		$1.39M Buy
11,221
+900
+9% +$114K ﹤0.01% 789
2019
Q1 		$1.36M Sell
10,321
-188
-2% -$25.4K ﹤0.01% 774
2018
Q4 		$1.45M Buy
+10,509
New +$1.39M ﹤0.01% 727

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Aberdeen Group's ONC Position: Q1 2025 in Review

Aberdeen Group sold out of BeOne Medicines Ltd (ONC) in Q1 2025, closing a stake of 14,913 shares — an estimated $2.75M sold.

Aberdeen Group first reported a position in ONC in Q4 2018 and held it in 25 quarters. The position peaked at $6.27M in Q3 2024. 267 funds tracked by Wall St. Rank hold ONC as of Q1 2025.

  • Aberdeen Group reported no remaining BeOne Medicines Ltd position as of Q1 2025 after selling out during the quarter.
  • Aberdeen Group sold 14,913 BeOne Medicines Ltd shares in Q1 2025, an estimated $2.75M.
  • Aberdeen Group first reported a position in BeOne Medicines Ltd in Q4 2018 and held it in 25 quarters.
  • Aberdeen Group's BeOne Medicines Ltd position peaked at $6.27M in Q3 2024.
  • 267 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2025.

Based on Aberdeen Group's 13F filing for Q1 2025, filed 13 May 2025.